RE:RE:US$10 Billion is a typical estimate for a M&A in 2023In January 2023, Riovant's CEO Matt Gline stated “Big pharma companies, although they are clearly focused and constrained on being efficient with R&D spend, are in many cases swimming in cash right now. Capital is not a concern for big pharma companies.“
Then as I posted here in March 2023 - “ Inflation is a driver for Big Pharma companies like Pfizer, with large cash reserves, to put that cash to work in the form of M&A activites - given the fact that inflation is eroding the purchasing power of Big Pharma's cash reserves and has the effect of increasing the cost of debt financing.
Furthermore Big Pharma's patent cliff is another driver that will have global pharma companies acquiring innovative companies like ONCY with "bolt-on" assets that address unmet clinical treatment needs in the range of US$10 Billion.“
In April 2023 Merck acquired Prometheus Biosciences for US$11 Billion.
Last week (October 23, 2023) Roche acquired Riovant's Phase 2 subsidiary Televant for US$7.2 Billion.
https://www.lek.com/sites/default/files/PDFs/2420_hub-spoke.pdf
https://www.nytimes.com/2023/06/27/us/politics/vivek-ramaswamy-wealth.html